Recently, ophthalmic medical technology company Glaukos announced its financial performance for the third quarter of 2025, showcasing remarkable growth momentum. The company's total revenue reached $133.5 million, exceeding analysts' expectations of $122.5 million, and representing a year-on-year increase of 38%. This impressive performance is mainly attributed to the strong performance of the company's core business in the field of glaucoma treatment.

The sales related to glaucoma reached $110.2 million, a significant increase of 45% compared to the same period last year. Among them, the U.S. market performed particularly well, with sales of $80.8 million, a year-on-year growth of as much as 57%. This data highlights Glaukos's leading position and continuous expansion capability in the North American ophthalmic medical market.

In terms of profitability, Glaukos has also made significant progress. The company's gross margin is approximately 84%, an improvement of about 200 basis points compared to the same period last year. Although the adjusted loss per share was $0.16, it still outperformed the market expectation of a $0.26 loss, demonstrating the company's efforts in controlling costs and improving operational efficiency are yielding results.

Looking ahead, Glaukos management remains optimistic about the company's prospects. They have raised their revenue forecast for the fiscal year 2025, expecting total revenue to reach between $490 million and $495 million, higher than the previous market consensus of $484.6 million. Notably, the company also disclosed its preliminary revenue target for the fiscal year 2026 for the first time, estimating it will reach between $600 million and $620 million, reflecting management's confidence in the company's long-term growth potential.

Glaukos's financial report not only showcases the company's innovation and market competitiveness in the field of ophthalmic medical technology but also outlines a clear future development blueprint for investors. With the global aging population trend intensifying, the incidence of ophthalmic diseases is expected to continue rising. As a leading enterprise in the industry, Glaukos is poised to maintain its leading position in this rapidly growing market.